Erez Chimovits insider trades
Open-market stock purchases and sales by Erez Chimovits, Director at ADARx Pharmaceuticals, Inc, from SEC Form 4 filings since Oct 18, 2018.
Track record: 33% of 15 scored buys are up 5% or more since purchase, averaging -33%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought (not open market) | — |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought (not open market) | — |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought (not open market) | — |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought (not open market) | — |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought | $1M |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought (not open market) | — |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought (not open market) | — |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought (not open market) | — |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc | Bought (not open market) | — |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc | Bought (not open market) | — |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc | Bought | $30M |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc | Bought | $4.9M |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc | Bought (not open market) | — |
| Aug 5, 2026 | BRVE Braveheart Bio, Inc | Bought (not open market) | — |
| Jun 9, 2026 | UPB Upstream Bio, Inc | Bought (not open market) | — |
Companies traded
- ADRX ADARx Pharmaceuticals, Inc: 1 buy, last Sep 28, 2026
- BRVE Braveheart Bio, Inc: 2 buys, last Aug 7, 2026
- UPB Upstream Bio, Inc: 2 buys, last Jun 9, 2026
- ACET Adicet Bio, Inc: other filings, last Feb 12, 2021
- LOGC LogicBio Therapeutics, Inc: 4 buys, last Oct 1, 2020
- PHGE BiomX Inc: 7 buys, last Mar 25, 2020
- NVUS Novus Therapeutics, Inc: 1 buy, 1 sale, last Jan 14, 2020